Plain-English translation of NCT06551519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study is watching how a specific blood marker called serum neurofilament (sNfL) can help doctors make better treatment decisions for people with relapsing multiple sclerosis. Researchers want to understand whether measuring this marker in your blood helps predict how your disease is progressing and whether it leads to better care—whether you're switching to ofatumumab or staying on your current treatment.
Right now, doctors have limited tools to predict which patients will do well on their current treatment or who might need to switch medications. This study aims to see if tracking this blood marker can help doctors personalize treatment plans and catch disease activity earlier, potentially improving outcomes for people living with multiple sclerosis.
You likely qualify if…
You likely don't qualify if…
You'll continue to see your regular doctor for routine MS appointments over about 2 years, just as you normally would—there are no extra study-only visits required. Your doctor will collect blood samples and health information as part of your standard care, and this data will be shared with the research team to track how the blood marker changes over time and how it relates to your disease activity and treatment decisions.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany